All In Biotech

Drug Trial Radar · NCT07013201

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

A Proof-of-concept Phase 2a, Double-blind, 2-arm Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle During a 16-week Treatment Period in Adult Subjects With Mild to Severe Palmoplantar Pustulosis

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Sep 11, 2025

Primary completion

Jun 4, 2027

Study completion Jun 4, 2027

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jun 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.

Conditions

  • Palmoplantar Pustulosis

Interventions

  • Delgocitinib creamDrug

    Topical application

  • Vehicle creamDrug

    Topical application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Achieving at Least 75% Improvement in PPP Area and Severity Index (PPPASI) Score from Baseline (PPPASI-75) at Week 16Time frame: Baseline to Week 16

Locations

40 sites in 5 countries. Site status is shown where the registry gives one.

  • LEO Pharma Investigational Site

    Fountain Valley, California · Recruiting

  • LEO Pharma Investigational Site

    Douglasville, Georgia · Recruiting

  • LEO Pharma Investigational Site

    West Bloomfield, Michigan · Recruiting

  • LEO Pharma Investigational Site

    Elmhurst, New York · Recruiting

  • LEO Pharma Investigation Site

    Mayfield Heights, Ohio · Recruiting

  • LEO Pharma Investigational Site

    Portland, Oregon · Recruiting

  • LEO Pharma Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • LEO Pharma Investigational Site

    Calgary, Alberta, Canada · Recruiting

  • LEO Pharma Investigational Site

    Edmonton, Alberta, Canada · Recruiting

  • LEO Pharma Investigational Site

    Surrey, British Columbia, Canada · Recruiting

  • LEO Pharma Investigational Site

    Winnipeg, Manitoba, Canada · Recruiting

  • LEO Pharma Investigational Site

    Fredericton, New Brunswick, Canada · Recruiting

  • LEO Pharma Investigational Site

    Hamilton, Ontario, Canada · Recruiting

  • LEO Pharma Investigational Site

    Hamilton, Ontario, Canada · Completed

  • LEO Pharma Investigational Site

    Markham, Ontario, Canada · Recruiting

  • LEO Pharma Investigational Site

    Waterloo, Ontario, Canada · Recruiting

  • LEO Pharma Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • LEO Pharma Investigational Site

    Bad Bentheim, Germany · Recruiting

  • LEO Pharma Investigational Site

    Dresden, Germany · Recruiting

  • LEO Pharma Investigational Site

    Göttingen, Germany · Recruiting

  • LEO Pharma Investigational Site

    Hamburg, Germany · Recruiting

  • LEO Pharma Investigational Site

    Kiel, Germany · Recruiting

  • LEO Pharma Investigational Site

    Lübeck, Germany · Recruiting

  • LEO Pharma Investigational Site

    Manheim, Germany · Recruiting

  • LEO Pharma Investigational Site

    Münster, Germany · Recruiting

  • LEO Pharma Investigational Site

    Osnabrück, Germany · Recruiting

  • LEO Pharma Investigational Site

    Witten, Germany · Recruiting

  • LEO Pharma Investigational Site

    Bialystok, Poland · Recruiting

  • LEO Pharma Investigational Site

    Iwonicz-Zdrój, Poland · Completed

  • LEO Pharma Investigational Site

    Lodz, Poland · Recruiting

  • LEO Pharma Investigational Site

    Lublin, Poland · Recruiting

  • LEO Pharma Investigational Site

    Rzeszów, Poland · Recruiting

  • LEO Pharma Investigational Site

    Warsaw, Poland · Recruiting

  • LEO Pharma Investigational Site

    Wroclaw, Poland · Recruiting

  • LEO Pharma Investigational Site

    Wroclaw, Poland · Recruiting

  • LEO Pharma Investigational Site

    Bristol, United Kingdom · Recruiting

  • LEO Pharma Investigational Site

    London, United Kingdom · Recruiting

  • LEO Pharma Investigational Site

    Newcastle upon Tyne, United Kingdom · Recruiting

  • LEO Pharma Investigational Site

    Salford, United Kingdom · Recruiting

  • LEO Pharma Investigational Site

    Stourbridge, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.